226 related articles for article (PubMed ID: 34871308)
1. Neutralizing antibody responses over time in demographically and clinically diverse individuals recovered from SARS-CoV-2 infection in the United States and Peru: A cohort study.
Karuna S; Li SS; Grant S; Walsh SR; Frank I; Casapia M; Trahey M; Hyrien O; Fisher L; Miner MD; Randhawa AK; Polakowski L; Kublin JG; Corey L; Montefiori D;
PLoS Med; 2021 Dec; 18(12):e1003868. PubMed ID: 34871308
[TBL] [Abstract][Full Text] [Related]
2. Evaluating the Association of Clinical Characteristics With Neutralizing Antibody Levels in Patients Who Have Recovered From Mild COVID-19 in Shanghai, China.
Wu F; Liu M; Wang A; Lu L; Wang Q; Gu C; Chen J; Wu Y; Xia S; Ling Y; Zhang Y; Xun J; Zhang R; Xie Y; Jiang S; Zhu T; Lu H; Wen Y; Huang J
JAMA Intern Med; 2020 Oct; 180(10):1356-1362. PubMed ID: 32808970
[TBL] [Abstract][Full Text] [Related]
3. Sex Disparities and Neutralizing-Antibody Durability to SARS-CoV-2 Infection in Convalescent Individuals.
Markmann AJ; Giallourou N; Bhowmik DR; Hou YJ; Lerner A; Martinez DR; Premkumar L; Root H; van Duin D; Napravnik S; Graham SD; Guerra Q; Raut R; Petropoulos CJ; Wrin T; Cornaby C; Schmitz J; Kuruc J; Weiss S; Park Y; Baric R; de Silva AM; Margolis DM; Bartelt LA
mSphere; 2021 Aug; 6(4):e0027521. PubMed ID: 34431693
[TBL] [Abstract][Full Text] [Related]
4. A longitudinal study of SARS-CoV-2-infected patients reveals a high correlation between neutralizing antibodies and COVID-19 severity.
Legros V; Denolly S; Vogrig M; Boson B; Siret E; Rigaill J; Pillet S; Grattard F; Gonzalo S; Verhoeven P; Allatif O; Berthelot P; Pélissier C; Thiery G; Botelho-Nevers E; Millet G; Morel J; Paul S; Walzer T; Cosset FL; Bourlet T; Pozzetto B
Cell Mol Immunol; 2021 Feb; 18(2):318-327. PubMed ID: 33408342
[TBL] [Abstract][Full Text] [Related]
5. Clinical, laboratory, and temporal predictors of neutralizing antibodies against SARS-CoV-2 among COVID-19 convalescent plasma donor candidates.
Boonyaratanakornkit J; Morishima C; Selke S; Zamora D; McGuffin S; Shapiro AE; Campbell VL; McClurkan CL; Jing L; Gross R; Liang J; Postnikova E; Mazur S; Lukin VV; Chaudhary A; Das MK; Fink SL; Bryan A; Greninger AL; Jerome KR; Holbrook MR; Gernsheimer TB; Wener MH; Wald A; Koelle DM
J Clin Invest; 2021 Feb; 131(3):. PubMed ID: 33320842
[TBL] [Abstract][Full Text] [Related]
6. Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Antibody Titers in Convalescent Plasma and Recipients in New Mexico: An Open Treatment Study in Patients With Coronavirus Disease 2019.
Bradfute SB; Hurwitz I; Yingling AV; Ye C; Cheng Q; Noonan TP; Raval JS; Sosa NR; Mertz GJ; Perkins DJ; Harkins MS
J Infect Dis; 2020 Oct; 222(10):1620-1628. PubMed ID: 32779705
[TBL] [Abstract][Full Text] [Related]
7. Early and High SARS-CoV-2 Neutralizing Antibodies Are Associated with Severity in COVID-19 Patients from India.
Shrivastava S; Palkar S; Shah J; Rane P; Lalwani S; Mishra AC; Arankalle VA
Am J Trop Med Hyg; 2021 Jun; 105(2):401-406. PubMed ID: 34138748
[TBL] [Abstract][Full Text] [Related]
8. Longitudinal neutralizing antibody responses after SARS-CoV-2 infection: A convalescent cohort study in Taiwan.
Huang YF; Hsu FC; Wu JJ; Lin YL; Liu MT; Yang CH; Kuo HS; Chen YJ; Cheng CY; Lin HH; Liao CC; Chang CS; Liang JJ; Cheng WY; Huang JC; Chen CP; Cheng SH; Lin YC; Yang SH; Chou YJ
J Microbiol Immunol Infect; 2023 Jun; 56(3):506-515. PubMed ID: 36967265
[TBL] [Abstract][Full Text] [Related]
9. Quantifying Absolute Neutralization Titers against SARS-CoV-2 by a Standardized Virus Neutralization Assay Allows for Cross-Cohort Comparisons of COVID-19 Sera.
Oguntuyo KY; Stevens CS; Hung CT; Ikegame S; Acklin JA; Kowdle SS; Carmichael JC; Chiu HP; Azarm KD; Haas GD; Amanat F; Klingler J; Baine I; Arinsburg S; Bandres JC; Siddiquey MNA; Schilke RM; Woolard MD; Zhang H; ; Duty AJ; Kraus TA; Moran TM; Tortorella D; Lim JK; Gamarnik AV; Hioe CE; Zolla-Pazner S; Ivanov SS; Kamil JP; Krammer F; Lee B
mBio; 2021 Feb; 12(1):. PubMed ID: 33593976
[TBL] [Abstract][Full Text] [Related]
10. SARS-CoV-2 neutralizing antibody levels are correlated with severity of COVID-19 pneumonia.
Chen W; Zhang J; Qin X; Wang W; Xu M; Wang LF; Xu C; Tang S; Liu P; Zhang L; Liu X; Zhang Y; Yi C; Hu Z; Yi Y
Biomed Pharmacother; 2020 Oct; 130():110629. PubMed ID: 33406577
[TBL] [Abstract][Full Text] [Related]
11. [Shedding of SARS-CoV-2 Virus in COVID-19 Patients and Neutralizing Antibody Level].
Ayhancı T; Toptan H; Özer YE; Uzar S; Enül H; Adıay C; Sarac F; Dheir H; Köroğlu M; Hasöksüz M; Altındiş M
Mikrobiyol Bul; 2022 Jul; 56(3):416-431. PubMed ID: 35960235
[TBL] [Abstract][Full Text] [Related]
12. Kinetics of SARS-CoV-2 Specific and Neutralizing Antibodies over Seven Months after Symptom Onset in COVID-19 Patients.
Zhu L; Xu X; Zhu B; Guo X; Xu K; Song C; Fu J; Yu H; Kong X; Peng J; Huang H; Zou X; Ding Y; Bao C; Zhu F; Hu Z; Wu M; Shen H
Microbiol Spectr; 2021 Oct; 9(2):e0059021. PubMed ID: 34550000
[TBL] [Abstract][Full Text] [Related]
13. PASC (Post Acute Sequelae of COVID-19) is associated with decreased neutralizing antibody titers in both biological sexes and increased ANG-2 and GM-CSF in females.
Jansen EB; Ostadgavahi AT; Hewins B; Buchanan R; Thivierge BM; Sganzerla Martinez G; Goncin U; Francis ME; Swan CL; Scruten E; Bell J; Darbellay J; Facciuolo A; Falzarano D; Gerdts V; Fenton ME; Hedlin P; Kelvin DJ; Kelvin AA
Sci Rep; 2024 Apr; 14(1):9854. PubMed ID: 38684819
[TBL] [Abstract][Full Text] [Related]
14. Kinetic Characteristics of Neutralizing Antibody Responses Vary among Patients with COVID-19.
Li LH; Tu HW; Liang D; Wen CY; Li AA; Lin WY; Hu KQ; Hong WS; Li YP; Su J; Zhao ST; Li W; Yuan RY; Zhou PP; Hu FY; Tang XP; Ke CW; Ke BX; Cai WP
Biomed Environ Sci; 2021 Dec; 34(12):976-983. PubMed ID: 34981720
[TBL] [Abstract][Full Text] [Related]
15. Neutralizing Antibody Responses to SARS-CoV-2 in Korean Patients Who Have Recovered from COVID-19.
Kim YJ; Bae JY; Bae S; Hwang S; Kwon KT; Chang HH; Lee WK; Cui C; Lee GE; Kim SW; Park MS
Yonsei Med J; 2021 Jul; 62(7):584-592. PubMed ID: 34164955
[TBL] [Abstract][Full Text] [Related]
16. Longitudinal analysis of antibody dynamics in COVID-19 convalescents reveals neutralizing responses up to 16 months after infection.
Yang Y; Yang M; Peng Y; Liang Y; Wei J; Xing L; Guo L; Li X; Li J; Wang J; Li M; Xu Z; Zhang M; Wang F; Shi Y; Yuan J; Liu Y
Nat Microbiol; 2022 Mar; 7(3):423-433. PubMed ID: 35132197
[TBL] [Abstract][Full Text] [Related]
17. Immunologic memory to SARS-CoV-2 in convalescent COVID-19 patients at 1 year postinfection.
Hou H; Zhang Y; Tang G; Luo Y; Liu W; Cheng C; Jiang Y; Xiong Z; Wu S; Sun Z; Xu S; Fan X; Wang F
J Allergy Clin Immunol; 2021 Dec; 148(6):1481-1492.e2. PubMed ID: 34536418
[TBL] [Abstract][Full Text] [Related]
18. Outcomes of Convalescent Plasma with Defined High versus Lower Neutralizing Antibody Titers against SARS-CoV-2 among Hospitalized Patients: CoronaVirus Inactivating Plasma (CoVIP) Study.
Bartelt LA; Markmann AJ; Nelson B; Keys J; Root H; Henderson HI; Kuruc J; Baker C; Bhowmik DR; Hou YJ; Premkumar L; Cornaby C; Schmitz JL; Weiss S; Park Y; Baric R; de Silva AM; Lachiewicz A; Napravnik S; van Duin D; Margolis DM
mBio; 2022 Oct; 13(5):e0175122. PubMed ID: 36135380
[TBL] [Abstract][Full Text] [Related]
19. Surface-modified measles vaccines encoding oligomeric, prefusion-stabilized SARS-CoV-2 spike glycoproteins boost neutralizing antibody responses to Omicron and historical variants, independent of measles seropositivity.
Muñoz-Alía MÁ; Nace RA; Balakrishnan B; Zhang L; Packiriswamy N; Singh G; Warang P; Mena I; Narjari R; Vandergaast R; Peng K-W; García-Sastre A; Schotsaert M; Russell SJ
mBio; 2024 Feb; 15(2):e0292823. PubMed ID: 38193729
[TBL] [Abstract][Full Text] [Related]
20. Persistence of neutralizing antibodies a year after SARS-CoV-2 infection in humans.
Haveri A; Ekström N; Solastie A; Virta C; Österlund P; Isosaari E; Nohynek H; Palmu AA; Melin M
Eur J Immunol; 2021 Dec; 51(12):3202-3213. PubMed ID: 34580856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
